



Universiteit
Leiden

The Netherlands

Pharmacologic and clinical aspects of isolated hepatic perfusion (IHP) of liver metastases of solid tumours

Iersel, L. van

Citation

Iersel, L. van. (2011, December 13). *Pharmacologic and clinical aspects of isolated hepatic perfusion (IHP) of liver metastases of solid tumours*.

Department of Clinical Oncology and Department of Surgery, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University.

Retrieved from <https://hdl.handle.net/1887/18240>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/18240>

Note: To cite this publication please use the final published version (if applicable).

Pharmacologic and clinical aspects of Isolated Hepatic Perfusion (IHP) of liver metastases of solid tumours

Liselot Valkenburg-van Iersel



ISBN: 978-94-6169-165-1

Printed by Optima Grafische Communicatie, Rotterdam

Cover design: Ans van Iersel, Dongen, The Netherlands, ansjejoanna@gmail.com

Copyright © 2011 by L.B.J. Valkenburg-van Iersel, The Netherlands

Pharmacologic and clinical aspects of Isolated Hepatic Perfusion (IHP) of liver metastases of solid tumours

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 13 december 2011

klokke 11:15 uur

door

Liselot Valkenburg-van Iersel

geboren te Tilburg

in 1978

Promotiecommissie:

Promotoren:	Prof. Dr. H. Gelderblom Prof. Dr. J.W.R. Nortier Prof. Dr. C.J.H. van de Velde
Co-promotor:	Dr. P.J.K. Kuppen
Overige leden:	Prof. Dr. J.H.M. Schellens Prof. Dr. J. Morreau Dr. C. Verhoef

Financial support for the publication of this thesis by Bronovo Research Foundation, SKOL, Amgen BV, Novartis Pharma BV, Pfizer BV, GlaxoSmithKline, AstraZenica BV, Sanofi-aventis BV, MSD BV, Bayer BV, Abbot BV and Roche Nederland BV is gratefully acknowledged.

Contents

Chapter 1	General Introduction. <i>Silberman & Silberman, Principles and Practice of Surgical Oncology, Second edition 2009; Ch. 48: p882-p891</i>	7
Chapter 2	Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. <i>Ann Surg Oncol. 2008 Jul;15(7):1891-8</i>	23
Chapter 3	Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. <i>Eur J Surg Oncol. 2007 Sep;33(7):874-81</i>	39
Chapter 4	Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. <i>Ann Oncol. 2008 Jun;19(6):1127-34</i>	57
Chapter 5	Management of isolated non-resectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. <i>Ann Oncol. 2010 Aug;21(8):1662-7</i>	75
Chapter 6	In vitro schedule-dependent interaction between melphalan and oxaliplatin in human colorectal cancer cell lines. <i>J Surg Res 2009 doi:10.1016/j.jss.2009.07.007</i>	89
Chapter 7	Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan: a phase I study. <i>Manuscript in preparation</i>	101
Chapter 8	The future of isolated hepatic perfusion for isolated liver metastases.	117
	Nederlandse Samenvatting	129
	Curriculum Vitae	135

